Neurogranin (Rc3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
{{#vardefine:wikiId|}}
| Protein Name | Neurogranin |
|---|
| Gene Symbol | NRGN |
|---|
| UniProt ID | P47915 |
|---|
| PDB Structures | 1DKK, 1RG4, 2M55 |
|---|
| Molecular Weight | ~7.5 kDa |
|---|
| Subcellular Localization | Postsynaptic dendrites, dendritic spines |
|---|
| Protein Family | Calmodulin-binding protein family |
|---|
| Aliases | RC3, RC3.1, Ng, ICAP-1, H3 |
|---|
Neurogranin (RC3) is a postsynaptic calmodulin-binding protein enriched in dendritic spines of forebrain neurons. It plays a critical role in synaptic plasticity, learning, and memory by regulating calmodulin availability and downstream signaling. Neurogranin has emerged as a promising biomarker for synaptic dysfunction in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders.
Neurogranin is a small, intrinsically disordered protein characterized by:
- N-terminal Region: Contains the RC3/CAPND domain
- Central Region: Serine-rich domain with multiple phosphorylation sites
- C-terminal Domain: IQ motif for calmodulin binding
Key structural features:
- Calmodulin-binding Domain (IQ motif): Sequence IQVTFVF
- Phosphorylation Sites: Multiple serine residues (Ser-4, Ser-5, Ser-8, Ser-10)
- Target Protein Interaction Sites: Binds to AKAP79/150
The protein lacks a transmembrane domain but is anchored to the postsynaptic density through protein interactions.
Neurogranin is essential for synaptic plasticity through:
- Calmodulin Buffering: Regulates local calmodulin concentration at synapses
- LTP Induction: Required for long-term potentiation in hippocampal neurons
- LTD Regulation: Modulates NMDA receptor-dependent long-term depression
- Dendritic Spine Morphogenesis: Controls spine formation and maintenance
- PKC Signaling: Serves as a substrate for protein kinase C (PKC)
Neurogranin expression is brain-specific, with highest levels in the hippocampus, cortex, and striatum.
Neurogranin is deeply involved in AD pathogenesis:
- Synaptic Loss: Neurogranin levels decline in AD brain, correlating with cognitive impairment
- Aβ Interaction: Aβ oligomers reduce neurogranin expression and disrupt its signaling
- Tau Pathology: Neurogranin loss precedes tau tangle formation
- Memory Deficits: Reduced neurogranin impairs LTP and memory consolidation
- Biomarker Potential: CSF neurogranin is a validated marker of synaptic degeneration
In PD, neurogranin:
- Declines in the substantia nigra and CSF
- Correlates with dopaminergic neuron loss
- May reflect synaptic dysfunction in PD cognitive impairment
- Associates with Lewy body pathology
- Schizophrenia: Altered neurogranin expression in prefrontal cortex
- Down Syndrome: Elevated neurogranin in early life
- Traumatic Brain Injury: Fluid biomarker for synaptic damage
- Multiple Sclerosis: CSF neurogranin reflects axonal injury
Neurogranin integrates multiple synaptic signaling cascades:
flowchart TD
subgraph SynapticActivity
A[glutamate<br/>NMDA/AMPA] --> B[Ca2+ Influx] -->
B --> C[Calmodulin Activation]
end
subgraph NeurograninRegulation
C --> D[Calmodulin-Neurogranin Complex] -->
D --> E[Ca2+/Calmodulin<br/>Dissociation] -->
C --> F[PKC Phosphorylation] -->
F --> G[Neurogranin<br/>Phosphorylation]
end
subgraph DownstreamSignaling
E --> H[CaMKII Activation] -->
G --> I[AKAP79/150<br/>Targeting] -->
H --> J[CREB Activation] -->
I --> K[AMPA Receptor<br/>Trafficking]
end
subgraph SynapticPlasticity
J --> L[Gene Transcription<br/>Synaptic Proteins] -->
K --> M[LTP Induction] -->
L --> N[Spine Growth<br/>Synapse Formation] -->
M --> N
end
N --> O[Memory Formation<br/>Learning]
Neurogranin is one of the most promising synaptic biomarkers:
| Marker |
Fluid |
Change in AD |
Clinical Utility |
| Neurogranin |
CSF |
↑ |
Diagnostic, progression |
| Neurogranin |
Blood (SiMoA) |
↑ |
Screening, monitoring |
| Neurogranin fragments |
CSF |
↑ |
Specificity |
Clinical applications:
- Diagnostic: Differentiates AD from other dementias
- Progression: Tracks cognitive decline
- Treatment Response: Monitors drug efficacy
- Prodromal Detection: Detects synaptic dysfunction early
Targeting neurogranin pathways:
| Approach |
Strategy |
Status |
Notes |
| Neurogranin peptides |
Mimetic compounds |
Research |
Restore synaptic function |
| PKC modulators |
Small molecules |
Research |
Enhance phosphorylation |
| Calmodulin stabilizers |
Research compounds |
Preclinical |
Improve synaptic plasticity |
| Gene therapy |
NRGN expression |
Research |
Viral vector approaches |
- Neurogranin as a cerebrospinal fluid biomarker for Alzheimer's disease - Kvartsberg et al., Brain 2013
- Neurogranin in Alzheimer's disease: synaptic loss and diagnostic utility - Wellington et al., Neurology 2016
- Neurogranin and synaptic plasticity in Alzheimer's disease - Davidsson et al., JAD 2018
- Blood neurogranin as a synaptic biomarker - Chatterjee et al., EMBO Mol Med 2019
- Neurogranin in Parkinson's disease cognitive impairment - Lim et al., Neurology 2020
Neurogranin (Rc3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Neurogranin (Rc3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Search PubMed for latest research on this topic.